Johnson & Johnson Q4 Profit Decreases

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its top-selling medicines, Stelara, to go off patent in the coming weeks.Fourth-quarter sales,
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the look-back and look-ahead on an earnings call,
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Rise of vaccine distrust - why more of us are questioning jabs
And regular polling carried out by YouGov suggests adults are increasingly likely to say that vaccines have harmful side ...
Don’t Call Kennedy a Vaccine Skeptic. Call Him What He Is: A Cynic.
Mr. Kennedy, on the other hand, is a vaccine cynic, failing to accept studies that refute his beliefs. He claims that the ...
DeSantis reasserts COVID vaccine dangers as final grand jury report finds no laws were broken
With a state grand jury report released Wednesday, Florida Gov. Ron DeSantis doubled down on the message he delivered often ...
Exclusive: Kennedy played key role in Gardasil vaccine case against Merck
Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...
Milwaukee Journal Sentinel18d
PolitiFact: Yes, there have been placebo-controlled studies on childhood vaccines
Asked on WISN's "Upfront" on Nov. 17 about his praise for Kennedy and false claims about vaccines causing autism, Johnson ...
Johnson & Johnson (JNJ) Receives a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...
Opinion
Williamsport Sun-Gazette12dOpinion
Vaccines are still our best protection against infection
With the coming of a new year—and a new administration—there have been unsettling indications that some long-standing public health policies and evidence-based healthcare recommendations may be ...
Hosted on MSN1d
Johnson & Johnson Issues Guidance for Higher 2025 Results Following Fourth-Quarter Beat
Johnson & Johnson's (JNJ) fourth-quarter results topped market expectations while the healthcare products conglomerate anticipates results in 2025 to be higher than the previous year. The company sees ...
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...